Supply Chain Documentation for Retatrutide: What Your Practice Needs to Maintain for a Defensible Position

When a clinic operates under an IRB protocol for retatrutide, the quality of the supply chain documentation is as important as the quality of the compound itself. If your practice is ever investigated — by a state medical board, a plaintiff's attorney, or a federal regulatory body — your supply chain documentation will be one of the first things examined. Here is what you need to maintain.

A Certificate of Analysis is the primary quality document for any pharmaceutical or research-grade compound. For retatrutide, your COA should include:

• Identity testing: Confirmation that the compound is what it is represented to be, typically through mass spectrometry or HPLC analysis
• Purity testing: The percentage of the compound that is the target molecule, with acceptable purity thresholds clearly stated
• Potency testing: Confirmation that the compound meets the stated concentration
• Sterility testing: For injectable compounds, confirmation that the product is free of microbial contamination
• Endotoxin testing: For injectable compounds, confirmation that bacterial endotoxin levels are within acceptable limits
• Heavy metals testing: Confirmation that the compound does not contain heavy metal contaminants above acceptable thresholds

A COA that covers only identity and purity is not sufficient for a compound being administered to human patients. Sterility and endotoxin testing are non-negotiable for injectables.

Chain of custody documentation tracks the compound from the point of manufacture to the point of administration. For retatrutide, this means:

• Manufacturer documentation: Who manufactured the compound, under what conditions, and with what quality controls
• Shipping documentation: How the compound was shipped, at what temperature, and whether cold chain integrity was maintained throughout transit
• Receipt documentation: When the compound was received, by whom, and what the condition of the shipment was upon receipt
• Storage documentation: How the compound is stored in your facility, at what temperature, and how storage conditions are monitored
• Dispensing documentation: When the compound was dispensed, to which patient, at what dose, and by whom

This documentation creates an auditable record that demonstrates the compound was handled appropriately from manufacture to administration.

Retatrutide is a peptide compound that requires cold chain storage — typically 2–8°C for short-term storage, with some formulations requiring frozen storage. Temperature excursions can degrade the compound and affect both potency and safety.

Your temperature monitoring records should include:

• Continuous temperature logs for your storage equipment
• Documentation of any temperature excursions, including the duration, the maximum/minimum temperature reached, and the action taken
• Calibration records for your temperature monitoring equipment

If you cannot demonstrate that your storage conditions were maintained, you cannot demonstrate that the compound you administered was the same compound described in your COA.

Your documentation should include records of how you vetted your supplier. This means:

• The supplier's accreditation and quality certifications
• Any site visit records or third-party audit reports
• The supplier's standard operating procedures for manufacturing and quality control
• Any communications with the supplier about quality issues or concerns

A supplier who cannot provide this documentation is not a supplier you should be working with for a compound being administered to human patients.

Under federal regulations governing human subjects research, research records must be retained for a minimum of three years after the completion of the study. Some state regulations require longer retention periods. Your IRB may specify additional retention requirements in your protocol approval.

Build a document retention system before you start. Trying to reconstruct supply chain documentation after the fact is difficult, time-consuming, and often incomplete.

When your documentation is complete and well-organized, it demonstrates several things to any investigator or reviewer:

1. You knew what you were administering — the compound was properly identified and tested
2. You knew it was safe to administer — sterility and endotoxin testing were completed
3. You maintained its integrity — cold chain and storage conditions were documented
4. You can account for every unit — chain of custody is complete from manufacture to patient

This is the documentation foundation of a defensible compliance position. Without it, you are relying on the hope that nothing goes wrong. With it, you have a documented record that demonstrates professional, responsible clinical practice.